Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy
- PMID: 31523806
- PMCID: PMC6745517
- DOI: 10.1002/14651858.CD011192.pub3
Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy
Abstract
Background: The hypertensive disorders of pregnancy include pre-eclampsia, gestational hypertension, chronic hypertension, and undefined hypertension. Pre-eclampsia is considerably more prevalent in low-income than in high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half of pregnancy reduces the serious consequences of pre-eclampsia, but has limited effect on the overall risk of pre-eclampsia. It is important to establish whether calcium supplementation before, and in early pregnancy (before 20 weeks' gestation) has added benefit. Such evidence could count towards justification of population-level interventions to improve dietary calcium intake, including fortification of staple foods with calcium, especially in contexts where dietary calcium intake is known to be inadequate. This is an update of a review first published in 2017.
Objectives: To determine the effect of calcium supplementation, given before or early in pregnancy and for at least the first half of pregnancy, on pre-eclampsia and other hypertensive disorders, maternal morbidity and mortality, and fetal and neonatal outcomes.
Search methods: We searched the Cochrane Pregnancy and Childbirth Trials Register (31 July 2018), PubMed (13 July 2018), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP; 31 July 2018), and reference lists of retrieved studies.
Selection criteria: Eligible studies were randomised controlled trials (RCT) of calcium supplementation, including women not yet pregnant, or women in early pregnancy. Cluster-RCTs, quasi-RCTs, and trials published as abstracts were eligible, but we did not identify any.
Data collection and analysis: Two review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked them for accuracy. They assessed the quality of the evidence for key outcomes using the GRADE approach.
Main results: Calcium versus placeboWe included one study (1355 women), which took place across multiple hospital sites in Argentina, South Africa, and Zimbabwe. Most analyses were conducted only on 633 women from this group who were known to have conceived, or on 579 who reached 20 weeks' gestation; the trial was at moderate risk of bias due to high attrition rates pre-conception. Non-pregnant women with previous pre-eclampsia received either calcium 500 mg daily or placebo, from enrolment until 20 weeks' gestation. All participants received calcium 1.5 g daily from 20 weeks until birth.Primary outcomes: calcium supplementation commencing before conception may make little or no difference to the risk of pre-eclampsia (69/296 versus 82/283, risk ratio (RR) 0.80, 95% confidence interval (CI) 0.61 to 1.06; low-quality evidence). For pre-eclampsia or pregnancy loss or stillbirth (or both) at any gestational age, calcium may slightly reduce the risk of this composite outcome, however the 95% CI met the line of no effect (RR 0.82, 95% CI 0.66 to 1.00; low-quality evidence). Supplementation may make little or no difference to the severe maternal morbidity and mortality index (RR 0.93, 95% CI 0.68 to 1.26; low-quality evidence), pregnancy loss or stillbirth at any gestational age (RR 0.83, 95% CI 0.61 to 1,14; low-quality evidence), or caesarean section (RR 1.11, 95% CI 0.96 to 1,28; low-quality evidence).Calcium supplementation may make little or no difference to the following secondary outcomes: birthweight < 2500 g (RR 1.00, 95% CI 0.76 to 1.30; low-quality evidence), preterm birth < 37 weeks (RR 0.90, 95% CI 0.74 to 1.10), early preterm birth < 32 weeks (RR 0.79, 95% CI 0.56 to 1.12), and pregnancy loss, stillbirth or neonatal death before discharge (RR 0.82, 95% CI 0.61 to 1.10; low-quality evidence), no conception, gestational hypertension, gestational proteinuria, severe gestational hypertension, severe pre-eclampsia, severe pre-eclamptic complications index. There was no clear evidence on whether or not calcium might make a difference to perinatal death, or neonatal intensive care unit admission for > 24h, or both (RR 1.11, 95% CI 0.77 to 1.60; low-quality evidence).It is unclear what impact calcium supplementation has on Apgar score < 7 at five minutes (RR 0.43, 95% CI 0.15 to 1.21; very low-quality evidence), stillbirth, early onset pre-eclampsia, eclampsia, placental abruption, intensive care unit admission > 24 hours, maternal death, hospital stay > 7 days from birth, and pregnancy loss before 20 weeks' gestation.
Authors' conclusions: The single included study suggested that calcium supplementation before and early in pregnancy may reduce the risk of women experiencing the composite outcome pre-eclampsia or pregnancy loss at any gestational age, but the results are inconclusive for all other outcomes for women and babies. Therefore, current evidence neither supports nor refutes the routine use of calcium supplementation before conception and in early pregnancy.To determine the overall benefit of calcium supplementation commenced before or in early pregnancy, the effects found in the study of calcium supplementation limited to the first half of pregnancy need to be added to the known benefits of calcium supplementation in the second half of pregnancy.Further research is needed to confirm whether initiating calcium supplementation pre- or in early pregnancy is associated with a reduction in adverse pregnancy outcomes for mother and baby. Research could also address the acceptability of the intervention to women, which was not covered by this review update.
Conflict of interest statement
Justus Hofmeyr is author of one study included in the review and did not participate in decisions regarding this study (Hofmeyr 2019). Two of the other review authors, who are not directly involved with the trial, evaluated the trial for inclusion, assessed risk of bias, and carried out data extraction and GRADE assessments. Alternative Discovery & Development, GlaxoSmithKline (GSK) Medicines Research Centre, UK, partnered with the same study to collect blood samples from a sub‐group of participants in the trial for an independent, open‐innovation pre‐eclampsia biomarker study, following a separate protocol, which was approved by the trial ethics committee. Apart from direct funding to the largest site (Chris Hani Baragwanath Hospital) specifically for the costs of this blood sample collection, GSK provided no funding to the main trial, and did not participate in any aspect of the main trial.
Sarah Manyame is an investigator on Hofmeyr 2019; however, she was not involved in any decisions relating to the trial. Two of the other review authors, who are not directly involved with the trial, evaluated the trial for inclusion, assessed risk of bias, and carried out data extraction and GRADE assessments. Alternative Discovery & Development, GlaxoSmithKline (GSK) Medicines Research Centre, UK, partnered with the same study to collect blood samples from a sub‐group of participants in the trial for an independent, open‐innovation pre‐eclampsia biomarker study, following a separate protocol, which was approved by the trial ethics committee. Apart from direct funding to the largest site (Chris Hani Baragwanath Hospital) specifically for the costs of this blood sample collection, GSK provided no funding to the main trial, and did not participate in any aspect of the main trial.
Nancy Medley's contribution to this review was financially supported by the World Health Organization.
Myfanwy J Williams is employed by the University of Liverpool as a Research Associate for Cochrane Pregnancy and Childbirth. Her role is supported by the World Health Organization.
Figures
![1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-AFig-FIG01.gif)
![2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-AFig-FIG02.gif)
![1.1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-01.gif)
![1.2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-02.gif)
![1.3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-03.gif)
![1.4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-04.gif)
![1.5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-05.gif)
![1.6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-06.gif)
![1.7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-07.gif)
![1.8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-08.gif)
![1.9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-09.gif)
![1.10](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-10.gif)
![1.11](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-11.gif)
![1.12](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-12.gif)
![1.13](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-13.gif)
![1.14](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-14.gif)
![1.15](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-15.gif)
![1.16](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-16.gif)
![1.17](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-17.gif)
![1.18](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-18.gif)
![1.19](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-19.gif)
![1.20](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-20.gif)
![1.21](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-21.gif)
![1.22](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-22.gif)
![1.23](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-23.gif)
![1.24](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-24.gif)
![1.25](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-25.gif)
![1.26](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-26.gif)
![1.27](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-27.gif)
![1.28](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-28.gif)
![1.29](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-29.gif)
![1.30](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-30.gif)
![1.31](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-31.gif)
![1.32](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-001-32.gif)
![2.1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-002-01.gif)
![2.2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-002-02.gif)
![2.3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-002-03.gif)
![2.4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-002-04.gif)
![2.5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6745517/bin/nCD011192-CMP-002-05.gif)
Update of
-
Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy.Cochrane Database Syst Rev. 2017 Sep 26;9(9):CD011192. doi: 10.1002/14651858.CD011192.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Sep 16;9:CD011192. doi: 10.1002/14651858.CD011192.pub3. PMID: 28949421 Free PMC article. Updated. Review.
Similar articles
-
Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy.Cochrane Database Syst Rev. 2017 Sep 26;9(9):CD011192. doi: 10.1002/14651858.CD011192.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Sep 16;9:CD011192. doi: 10.1002/14651858.CD011192.pub3. PMID: 28949421 Free PMC article. Updated. Review.
-
Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.Cochrane Database Syst Rev. 2018 Oct 1;10(10):CD001059. doi: 10.1002/14651858.CD001059.pub5. Cochrane Database Syst Rev. 2018. PMID: 30277579 Free PMC article.
-
Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.Cochrane Database Syst Rev. 2014 Jun 24;(6):CD001059. doi: 10.1002/14651858.CD001059.pub4. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2018 Oct 01;10:CD001059. doi: 10.1002/14651858.CD001059.pub5. PMID: 24960615 Updated. Review.
-
Vitamin D supplementation for women during pregnancy.Cochrane Database Syst Rev. 2019 Jul 26;7(7):CD008873. doi: 10.1002/14651858.CD008873.pub4. Cochrane Database Syst Rev. 2019. PMID: 31348529 Free PMC article.
-
Omega-3 fatty acid addition during pregnancy.Cochrane Database Syst Rev. 2018 Nov 15;11(11):CD003402. doi: 10.1002/14651858.CD003402.pub3. Cochrane Database Syst Rev. 2018. PMID: 30480773 Free PMC article.
Cited by
-
Cohort profile: the Environmental Reproductive and Glucose Outcomes (ERGO) Study (Boston, Massachusetts, USA) - a prospective pregnancy cohort study of the impacts of environmental exposures on parental cardiometabolic health.BMJ Open. 2024 May 8;14(5):e079782. doi: 10.1136/bmjopen-2023-079782. BMJ Open. 2024. PMID: 38719310 Free PMC article.
-
Calcium supplementation in pregnancy: An analysis of potential determinants in an under-resourced setting.PLoS One. 2023 Oct 5;18(10):e0292303. doi: 10.1371/journal.pone.0292303. eCollection 2023. PLoS One. 2023. PMID: 37796953 Free PMC article.
-
Identifying Foods That Optimize Intake of Key Micronutrients During Pregnancy.J Nutr. 2023 Oct;153(10):3012-3022. doi: 10.1016/j.tjnut.2023.08.012. Epub 2023 Aug 19. J Nutr. 2023. PMID: 37604382
-
Vitamins and minerals, education, and self-care need during preconception to 1000 days of life in Southeast Asia: An expert panel opinion.SAGE Open Med. 2023 May 19;11:20503121231173377. doi: 10.1177/20503121231173377. eCollection 2023. SAGE Open Med. 2023. PMID: 37223672 Free PMC article. Review.
-
Selecting a dietary supplement with appropriate dosing for 6 key nutrients in pregnancy.Am J Clin Nutr. 2023 Apr;117(4):823-829. doi: 10.1016/j.ajcnut.2022.12.018. Am J Clin Nutr. 2023. PMID: 37019542 Free PMC article.
References
References to studies included in this review
Hofmeyr 2019 {published data only}
-
- Hofmeyr GJ. Protocol 11PRT/4028: Long term calcium supplementation in women at high risk of pre‐eclampsia: a randomised, placebo‐controlled trial (PACTR201105000267371). www.thelancet.com/protocol‐reviews/11PRT‐4028 2011.
-
- Hofmeyr GJ, Betrán AP, Singata‐Madliki M, Cormick G, Munjanja SP, Fawcus S, et al. Calcium and Pre‐eclampsia Study Group. Pre‐pregnancy and early pregnancy calcium supplementation among women at high risk of pre‐eclampsia: a multicenter, double‐blind, randomised, placebo‐controlled trial. Lancet 2019;393(10169):330‐9. - PMC - PubMed
-
- Hofmeyr GJ, Seuc AH, Betrán AP, Purnat TD, Ciganda A, Munjanja SP, et al. The effect of calcium supplementation on blood pressure in non‐pregnant women with previous pre‐eclampsia: an exploratory, randomized placebo controlled study. Pregnancy Hypertension 2015;5(4):273‐9. - PubMed
References to studies excluded from this review
Rumiris 2006 {published data only}
-
- Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A. Lower rate of pre‐eclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertension in Pregnancy 2006;25(3):241‐53. - PubMed
References to ongoing studies
Fawzi 2017 {published data only}
-
- CTRI/2018/02/012119. A cluster randomized trial to demonstrate the equivalency of lower dose calcium supplementation during pregnancy for reducing preeclampsia and preterm birth. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21313 (first received 23 February 2018).
-
- NCT03350516. Demonstrating non‐inferiority of lower dose calcium supplementation during pregnancy for reducing preeclampsia and neonatal outcomes. clinicaltrials.gov/ct2/show/record/NCT03350516 (first received 22 November 2017).
Additional references
Belizan 1980
-
- Belizan JM, Villar J. The relationship between calcium intake and edema‐, proteinuria‐, and hypertension‐getosis: an hypothesis. American Journal of Clinical Nutrition 1980;33:2202‐10. - PubMed
Buppasiri 2015
-
- Buppasiri P, Lumbiganon P, Thinkhamrop J, Ngamjarus C, Laopaiboon M, Medley N. Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD007079.pub3] - DOI - PubMed
Centeno 2009
-
- Centeno V, Barboza GD, Marchionatti A, Rodriguez V, Talamoni NT. Molecular mechanisms triggered by low‐calcium diets. Nutritional Research Reviews 2009;22:163‐74. - PubMed
De‐Regil 2016
GRADE Handbook
-
- Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
GRADEpro GDT [Computer program]
-
- McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 20 July 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Griffith 1999
-
- Griffith LE, Guyatt GH, Cook RJ, Bucher HC, Cook DJ. The influence of dietary and non‐dietary calcium supplementation blood pressure: an updated meta‐analysis of randomized controlled trials. American Journal of Hypertension 1999;12(1):84‐92. - PubMed
Hamlin 1952
-
- Hamlin RH. The prevention of eclampsia and pre‐eclampsia. Lancet 1952;1:64‐8. - PubMed
Higgins 2011
-
- Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hofmeyr 2007
-
- Hofmeyr G, Duley L, Atallah A. Dietary calcium supplementation for prevention of pre‐eclampsia and related problems: a systematic review and commentary. BJOG: an International Journal of Obstetrics and Gynaecology 2007;114:933‐43. - PubMed
Hofmeyr 2008
-
- Hofmeyr GJ, Mlokoti Z, Nikodem VC, Mangesi L, Ferreira S, Singata M, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial. Hypertension in Pregnancy 2008;27:299‐304. - PubMed
Hofmeyr 2014
-
- Hofmeyr G, Belizán J, Dadelszen P, the Calcium and Pre‐eclampsia (CAP) Study Group. Low‐dose calcium supplementation for preventing pre‐eclampsia: a systematic review and commentary. BJOG: an International Journal of Obstetrics and Gynaecology 2014;121(8):951‐7. [DOI: 10.1111/1471-0528.12613] - DOI - PMC - PubMed
Hofmeyr 2018
Jarjou 2010
Li 2012
-
- Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC‐Heidelberg). Heart 2012;98:920‐5. - PubMed
Lyall 2013
-
- Lyall F, Robson SC, Bulmer JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. Hypertension 2013;62(6):1046‐54. - PubMed
Magee 2014
-
- Magee LA, Pels A, Helewa M, Rey E, Dadelszen P, on behalf of the Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertension 2014;4:105–45. - PubMed
Mol 2016
-
- Mol BW, Roberts CT, Thangaratinam S, Magee LA, Groot CJ, Hofmeyr GJ. Pre‐eclampsia. Lancet 2016;387:999‐1011. - PubMed
Palei 2013
Redman 2014
-
- Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre‐eclampsia – two placental causes of preeclampsia?. Placenta 2014;35 Suppl:S20‐5. - PubMed
Review Manager 2014 [Computer program]
-
- Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Villar 2006
-
- Villar J, Abdel‐Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. American Journal of Obstetrics and Gynecology 2006;194:639‐49. - PubMed
von Dadelszen 2016
von Dadelzsen 2004
-
- Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R, et al. The prediction of adverse maternal outcomes in preeclampsia. Journal of Obstetrics and Gynaecology Canada: JOGC 2004;26:871‐9. - PubMed
References to other published versions of this review
Hofmeyr 2014b
Hofmeyr 2017
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous